Skip to content Skip to main menu

SCIENCE

Clinical test of Lutemax2020TM

  • MPOD for subjects in both 12mg and supplementation groups increased significantly versus placebo at both 6-and 12-month visits (p<0.001 for all).
    PSR times and DG thresholds improved significantly from baseline compared to placebo at 6-and 12-month visits (p<0.001 for all).

Fig.1 Percent change from baseline at 6 and 12 months for all outline mreaures. Error bars±1 SD.Single astrisk denotes significant difference from baseline and placebo (p<0.05 level);double asterisk denotes significant differences from baseline,6-month measure, and placebo(p<0.05 level)

  • Lutemax2020 suplementation(24 mg daily)yielded significant improvement in MOPD,overall sleep quality, headache frequency, eye strain, eye fatigue,and all visual performance measures, versus placebo(p<0.05 for all).

Macular pigment optical density(MPOD)

After 6 months of lutein and Zeaxanthin 24mg intake, MOPD, DG(glare tolerance) and PSR(speed of recovery after glare) were significantly improved.

Effect on the body

After 6 moths of lutein Zeaxanthin 24 mg intake, headache,eye fatigue and sleep disorders were significantly improved.

  • Compared to placebo, serum concentrations of lutein and total zeaxanthin, for each of the supplement levels, were found increase signicantly from baseline after teo weeks of daily ingestion(p<0.001).Likewise,MOPD increased signicantly in all treatment groups(p<0.001)compared to placebo.

Lutein Concentration in Serum

Zeaxanthin concentration in serum

Macular Pigment Optical Density(MOPD)

  • MOPD increased significantly from baseline to month 3 increased for all L/Zi treatments over placebo.
    significant change in MOPD was observed in Group â…¢ and â…£ at week 8 to week 12(p<0.001>.

Table 2. MPOD (OD Units) Response by Week and Dose (Mean ± SD).

Bseline Week 2 Week 4 Week 6 Week 8 Week 10 Week 12
Group Ⅰ, placebo 0.44±0.29 0.45±0.27 0.48±0.33 0.48±0.34 0.54±0.40 0.49±0.33 0.47±0.29
Group Ⅱ,6mgL/1mg Zi 0.73±0.15 0.75±0.11 0.75±0.12 0.79±0.10 0.81±0.13 0.82±0.14 0.82±0.11
Group Ⅲ,10mgL/2mg Zi 0.42±0.25 0.45±0.24 0.49±0.26 0.51±0.29 0.54±0.33 0.54±0.31 0.56±0.31
Group Ⅳ,20mgL/4mg Zi 0.43±0.15 0.45±0.15 0.48±0.16 0.48±0.18 0.50±0.19 0.57±0.17 0.55±0.17
  • · MPOD : Macular Pigment Optical Density;
  • · OD : Optical Density

References

Eye and Vision (2016)3:30 l Foods (2017)6:47

Experimental Eye Researth (2016)151:1 l New Frontiers in Opthalmoiogy (2016)2:4